Product

OBT076

Aliases

MEN1309, OBT076, a CD205-directed antibody-drug conjugate

2 clinical trials

2 indications

Indication

Indication

Adenoid Cystic Carcinoma of the Head and Neck

Clinical trial

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

A Phase Ib Study of OBT076 or OBT076 Followed by Balstilimab in Patients With Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (AdCC) of the Head and Neck (H&N)

Status: Recruiting, Estimated PCD: 2026-09-01